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INTRODUCTION
Clinical mastitis is recognized worldwide to cause major economic losses in dairy cattle because of the loss in milk production and quality (De Graves & Fetrow, 1993; Watts et al., 1995) . It is estimated that 70% of the economic losses from this disease is caused by lower milk production, 14% to premature animal removal, 7% to milk wasting and 8% to veterinary expenses and treatments (Philpot & Nickerson, 1991) .
There is extensive literature about clinical mastitis including aetiology, pathogenesis, therapy and epidemiology. One main objective is towards the search for measures that upgrade the prevention, control and treatment of the clinical case. The selection of therapy must be based on the aetiology, disease acuteness and animal history.
A good antimicrobial therapy for bovine clinical mastitis is aimed at the elimination of the infectious agent by maintaining homogeneous concentrations above the MIC in the mammary gland for an adequate time. The antimicrobial therapy for the more severe cases is based on systemic and/or intramammary treatments with tetracyclines, b-lactams, cephalosporins, macrolides, aminoglycosides and sulphonamides (Watts et al., 1995; Morin et al., 1998) . Additionally, it is important to note that in the USA only one sulphonamide is approved for the use in lactating dairy cattle (sulphadimethoxine) and that trimethoprim± sulphonamide combinations are not approved for dairy cattle (Boeckman & Carlson, 1995) .
It has been shown that sulphonamides in combination with trimethoprim (TMP) are commonly used for broad spectrum antimicrobial therapy in veterinary medicine. The main indications in cattle are infections of the alimentary and urinary tract, mastitis and metritis.
There is information on the pharmacokinetic behaviour of the trimethoprim±sulphadiazine (TMP±SDZ) combination in lactating cows after intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) routes (Kaartinen et al., 1999) . The pharmacokinetic properties of this combination have been also investigated in calves (Shoaf et al., 1987) and young cattle (Clarke et al., 1989) . Some information exists on the pharmacokinetic behaviour of TMP in lactating cows (Nielsen et al., 1978) and SDZ in adult cattle after i.v. administration (Nouws et al., 1988) . However, there are only limited data on the use of intramammary infusion of the (TMP±SDZ) combination in lactating cows.
The selection of an antimicrobial in cows must also consider its elimination time from the milk to avoid residual levels of antimicrobials. There are several factors determining an antimicrobial withdrawal time, such as its physical and chemical structure, excipients, route of administration, age, animal condition or disease, etc. (Prescott & Baggot, 1991) . Thus, several studies are needed when a new antimicrobial agent or a new formulation is produced to avoid the presence of its residues in animal products, such as milk.
The aim of the present study was to analyse the time-related concentrations in milk of a combination of (TMP±SDZ) intramammary formulated infusion and its relationship with MICs of clinical mastitis isolated pathogenic bacteria; also suggesting the corresponding withdrawal time in accordance to the established maximum residual limits (MRLs) of different international organizations.
MATERIALS AND METHODS

Isolation and identi®cation of pathogenic bacterial strains and MICs determination
Experimental design. Milk samples were taken from 100 cows with clinical mastitis. The samples were collected aseptically as recommended by National Mastitis Council (1999) . The samples were transported to the laboratory at 4°C within 24 h of collection. The isolation and identi®cation of bacterial strains were performed using standard bacteriological methodology suggested by National Mastitis Council (1999).
The strains were stored at )30°C until used. When needed, the strains were grown on tryptose agar for Escherichia coli and Staphylococcus aureus, and blood agar for Streptococcus sp.
Antibacterial susceptibility test. Minimum inhibitory concentrations determination was performed following the recommendations of NCCLS (1993), using S. aureus ATCC 25923 and E. coli ATCC 25922 as control organisms. Stock solution of TMP (400 lg/mL) and SDZ (2000 lg/mL) at a 1:5 ratio was used. From this solution, twofold dilutions in Mueller Hinton pH 7.2 broth were prepared. After 18±24 h incubation at 37°C, the plates were read. MIC was de®ned as the lowest concentration of antimicrobial agent that completely prevented the visible growth of the organism. MIC 90 was de®ned as the concentration of antimicrobial agent able to inhibit the growth of 90% of a population of microorganisms.
Detection of TMP and SDZ in milk
Experimental design. Ten clinically healthy multiparous Holstein Friesan cows were used. The cows were lactating for at least 1 month and most were in late lactation. During the entire experiment the cows were housed in a stanchion barn, milked three times daily, and fed with a diet of good quality silage, hay and grain, according to the farm milk production system. Water was provided ad libitum. One to two weeks before the experiment began, the udders of the cows were examined clinically and milk samples were taken for bacteriological culture and milk somatic cell count (SCC). This procedure was repeated for 2 days before challenge. All cows had low SCC (< 250 000 cells/mL) in bulk milk. The experimental quarters used in the study were culturenegative and had milk SCC of < 150 000 cells/mL. All animals did not receive any treatment or feed containing antimicrobials for at least 8 weeks as described by Reichmuth et al. (1997) . To con®rm the absence of antimicrobial agents, a sample was taken (time 0) prior to the administration of the intramammary infusion.
A commercial intramammary infusion provided by Intervet Chile Ltda. (Avda. Pio´2460, 8th Floor, Of®ce 808, Providencia, Santiago, Chile), containing TMP (40 mg) and SDZ (200 mg) in oily excipient (up to 8 g), was administered to one mammary quarter of each animal. The udder was massaged to have a uniform distribution through the gland. The treatment was repeated three times at 12 h intervals. In order to avoid interference with the production and management of the milking farm and to maintain the treatment regime, additional milkings were performed as required prior to the intramammary infusion administration.
To assess SDZ and TMP concentrations in milk during therapy, milk samples (approximately 20 mL) from the treated mammary quarters were taken at 6, 12, 24, 30 and 36 h after ®rst administration. If any sampling time coincided with the normal farm milkings, the samples were taken before milking.
In order to de®ne the withdrawal time, milk samples from the treated mammary quarters were taken, before milking, at 24, 36, 48, 72, 84 and 96 h, after ®nishing the therapy. If any sampling time coincided with the normal farm milkings, the samples were taken before milking.
The samples were taken aseptically and stored at 4°C until arrival at the laboratory. All samples were kept frozen at )20°C until analysis. The analysis of samples was performed within 48 h of arrival.
Drug assay. Prior to SDZ and TMP determination in milk samples, the analytical methodologies were validated following the recommendations of Food and Drug Administration (FDA) (1994), and Veterinary International Committee for Harmonization (VICH) (1998), obtaining the limit of detection, quanti®cation, recovery rates and linearity of each methodology.
Analysis of TMP. Trimethoprim was assayed microbiologically, using Bacillus pumilus as test organism. Speci®city for TMP was derived by the addition of para-aminobenzoic acid (100 lg/mL) to the agar medium in order to negate the effect of the sulphonamide (Norbrook Laboratories, 1992b) . The concentration of TMP was determined by measuring the zone of inhibition with a Vernier calliper. The limit of quanti®cation was 0.025 lg/ mL with a mean inhibition halo of 1.3 0.08 cm. Standard curves were plotted using intervals of 0.025±0.4 lg TMP/mL milk with inhibition halos between 1.3 and 4.8 cm, respectively; the response was found to be linear and a good correlation was obtained between TMP concentrations and zone of inhibition (r 0.98). The recovery rate was 78%. Milk samples and standards were tested on plates in duplicate. When the inhibition halos of samples were bigger than those of the standard curve (> 4.8 cm), appropriate dilutions were prepared to fall in the range of the standard curve; the results were then multiplied by the corresponding dilution factors.
Analysis of SDZ. Sulphadiazine was analysed by reverse-phase, high-performance liquid chromatography (HPLC) (Norbrook Laboratories, 1992a .9 mm ID) were packed with 5 and 10 lm particles of dimetiloctadecilsylil silica, respectively. The eluant at a¯ow rate of 1.0 mL/min was a mixture of acetonitrile±0.017 M phosphoric acid (24±76) with a pH of 2.3 0.5.
The limit of detection was 0.05 lg/mL and the limit of quanti®cation was 0.07 lg/mL. Standard curves were plotted using intervals of 0.05±80 lg/mL SDZ/mL milk; the response was found to be linear and a good correlation was obtained between concentrations of SDZ and chromatographic area (r 0.98). The recovery rate was 81%. Milk samples and standards were tested in duplicate.
Data analysis. The drug concentrations in milk were analysed with a software based on statistical theory. The actual concentration of drugs in the milk sample for SDZ and TMP were calculated using the following formula:
where C is the drug concentration in the sample (lg/mL), A the drug concentration from the validated curves (lg/mL) and R the recovery rate.
RESULTS AND DISCUSSION
From 100 milk samples collected from clinical mastitis cows, 36 E. coli, 23 S. aureus and 14 Streptococcus sp. strains were isolated. These results are similar to those of previously published works, as clinical mastitis can be caused by bacteria that cannot be Depletion study of SDZ and TMP in milkdetected by routine microbiological identi®cation procedures (Kirk, 1991 3 ; Ruegg et al., 1992; Erskine et al., 1995) , by fungi (Pianta, 1987; Schoonderwoerd & Plante-Jenkins, 1988) or other causes such as traumas.
The MIC determination was carried out before determining the TMP and SDZ concentration in milk. Prior to MICs determination, we de®ned the TMP:SDZ stock solution ratio in which we should work. Although, the literature points out that the optimal plasma ratio is 1:20, we thought that the pharmacokinetic behaviour of these drugs should not be the same when administered intramammary compared with when they are used parenterally. Thus, we used a stock solution at the ratio of 1:5 considering the ratio of the drugs in the commercial intramammary infusion. Based upon the results obtained in the time-related TMP and SDZ concentration study, as it will be explained later on, the stock solution ratio of 1:5 made sense.
The MIC ranges for the TMP:SDZ association are presented in Table 1 . These were between 0.025:0.125 and 0.4:2 lg/mL for E. coli, 0.025:0.125 and 0.2:1 lg/mL for Streptococcus sp. and 0.1:0.5 and 1.6:8 lg/mL for S. aureus with MIC 90 of 0.2:1, 0.2:1 and 1.6:8 lg/mL, respectively. One E. coli and one S. aureus strain were found to be resistant to this combination.
These results con®rm that the in vitro MICs¯uctuate considerably depending on the pathogen under study. Limited information regarding the MICs of this combination exists. However, there is some information on MICs for TMP and SDZ separately, ranging from 0.1 to 0.5 and 3 to 10 lg/mL, respectively, against a variety of pathogens, such as E. coli, Salmonella sp., Pasteurella sp., Haemophillus sp. (Bushby, 1980) .
The time-related SDZ and TMP concentrations in milk during therapy and after ®nishing therapy are shown in Tables 2 and 3 . The treatment was repeated three times at 12 h. Additional milkings were performed as required prior to the intramammary infusion administration. *Samples taken before intramammary infusion administration to con®rm the absence of antimicrobial agents. ND: not detected. During therapy (up to 36 h from ®rst administration) TMP concentrations were detected in ranges of 0.25±4.79 lg/mL (Table 3) and SDZ in ranges of 1.36±33.17 lg/mL ( Table 2) . As mentioned, TMP concentrations were lower than those of SDZ which is expected because lower concentrations of TMP were administered.
As we compare the MICs from isolated strains with SDZ concentrations in milk, these were above MIC 90 for E. coli and Streptococcus sp. The case is different with S. aureus because the concentrations were below the MIC 90 at some sampling times during therapy.
According to these results, this combination may be effective against Streptococcus sp. isolated from clinical mastitis. For E. coli isolated from clinical mastitis, although some works point out that antibiotic treatment may not always be necessary because a spontaneous cure can occur (Pyo Èra Èla È & Syva Èja Èrvi, 1987; Erskine et al., 1990; Pyo Èra Èla È et al., 1992; Smith & Hogan, 1993) , this combination could be used as an alternative if the veterinarian decides to begin a treatment.
The use of this combination, according to our results, is not recommended in the case of S. aureus clinical mastitis because, as it was mentioned before, at some sampling times during therapy SDZ concentrations in milk were below the MIC 90 of this pathogen (Table 3, 4)  4 . No TMP was found in milk at 24 h after ®nishing therapy. Although the SDZ concentrations at each sampling time in each cow were different, at 84 h after ®nishing therapy all cows presented SDZ concentrations below 0.1 lg/mL. At 96 h no SDZ concentration was found in six animals although four animals of the experimental group still had concentrations of 0.07 lg/mL.
In order to de®ne the withdrawal time, it is important to consider the MRLs given by different international organizations. In the present work, we consider the MRL of 0.1 lg/mL given by The European Agency for the Evaluation of Medicinal Products (1999) for sulphonamides in different matrices (meat and milk). Based on our results and the before mentioned MRL (Fig. 1) we suggest a withdrawal time, as an average value, of 84 h for this TMP:SDZ combination administered three times by the intramammary route every 12 h and in cows milked three times daily.
Independently from our results and suggestions we have to mention that the Food and Drug Administration (1999) gives tolerances of 0.01 lg/mL to sulphonamides in milk. On the other hand, Food and Agricultural Organization/World Health Organization (1999) 5
gives an MRL of 0.025 lg/mL only for sulphamethazine unable to establish MRLs for other sulphonamides. If we consider these values, future work is needed to establish at which time SDZ concentrations are below those suggested by these organizations. * Samples taken before intramammary infusion administration to con®rm the absence of antimicrobial agents. Fig. 1 . Mean SDZ concentrations after ®nish-ing therapy and its relationship with the MRL (0.1 lg/mL). The bars about the mean points refer to standard deviations.
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